Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: CLLS

Cellectis S.A.

Healthcare | Biotechnology

No licensed closing price on file for CLLS. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (FY2025)$-2.15

Cellectis S.A. (NASDAQ: CLLS) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 20:47 UTC.

What Cellectis S.A. does

The company develops allogeneic CAR T-cell immunotherapy product candidates and has a significant collaboration with AstraZeneca through a Joint Research and Collaboration Agreement that reserves genetic targets for development. AstraZeneca holds substantial ownership and influence over the company, with the ability to nominate directors, creating potential conflicts of interest since some directors have relationships with AstraZeneca.

Summarized from Cellectis S.A.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (FY2025)$-2.15
Debt/equity3.41

Revenue, margins & earnings

FY2022: net loss $39M on revenue $3M$3MFY2022FY2023: net loss $26M on revenue $127M$127MFY2023FY2024: net loss $45M on revenue $151M$151MFY2024FY2025: net loss $822M on revenue $224M$224MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity
No insider transactions on file with the SEC for CLLS.
Source: SEC EDGAR · Last checked 2026-10-20
Top Institutional Holders (latest 13F)
Source: SEC EDGAR · As of 2026-Q2
  • B Group, Inc.3,281,501$9.84M0.0%
  • Long Focus Capital Management, LLC2,741,853$8.23M-0.1%
  • UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC2,644,881$7.93M-16.8%
View QoQ ownership changes →Full institutional ownership →

Company news

View all →

Questions this page answers

What does Cellectis S.A. do?

The company develops allogeneic CAR T-cell immunotherapy product candidates and has a significant collaboration with AstraZeneca through a Joint Research and Collaboration Agreement that reserves genetic targets for development.

When did CLLS last file with the SEC?

Cellectis S.A.'s most recent SEC filing on record is a 6-K filed 2026-06-25. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 20:47 UTC. This page is also available as JSON at /api/data?ticker=CLLS and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for CLLS and 5,000+ tickers.

Create a free account — keep CLLS
For your agent
GET /api/data?ticker=CLLS

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt